- Home
- GAME vs DARE Comparison
GAME vs DARE Comparison
Compare GAME & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- DARE
- Stock Information
- Founded
- GAME 2011
- DARE 2015
- Country
- GAME United States
- DARE United States
- Employees
- GAME N/A
- DARE N/A
- Industry
- GAME
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- DARE Health Care
- Exchange
- GAME Nasdaq
- DARE Nasdaq
- Market Cap
- GAME 27.2M
- DARE 26.3M
- IPO Year
- GAME 2009
- DARE N/A
- Fundamental
- Price
- GAME $1.90
- DARE $2.52
- Analyst Decision
- GAME Strong Buy
- DARE Strong Buy
- Analyst Count
- GAME 3
- DARE 3
- Target Price
- GAME $3.67
- DARE $12.50
- AVG Volume (30 Days)
- GAME 7.8M
- DARE 452.0K
- Earning Date
- GAME 08-13-2025
- DARE 08-11-2025
- Dividend Yield
- GAME N/A
- DARE N/A
- EPS Growth
- GAME N/A
- DARE N/A
- EPS
- GAME N/A
- DARE N/A
- Revenue
- GAME $99,579,536.00
- DARE $25,909.00
- Revenue This Year
- GAME $6.08
- DARE $99,756.91
- Revenue Next Year
- GAME $21.94
- DARE $119.77
- P/E Ratio
- GAME N/A
- DARE N/A
- Revenue Growth
- GAME 77.06
- DARE N/A
- 52 Week Low
- GAME $0.50
- DARE $2.11
- 52 Week High
- GAME $2.87
- DARE $4.60
- Technical
- Relative Strength Index (RSI)
- GAME 75.08
- DARE 41.75
- Support Level
- GAME $0.73
- DARE $2.37
- Resistance Level
- GAME $2.87
- DARE $2.54
- Average True Range (ATR)
- GAME 0.22
- DARE 0.14
- MACD
- GAME 0.13
- DARE -0.00
- Stochastic Oscillator
- GAME 53.88
- DARE 59.56
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.